SIMILARITIES AND DIFFERENCES IN THE PROPERTIES OF SUBSTITUTED BENZIMIDAZOLES - A COMPARISON BETWEEN PANTOPRAZOLE AND RELATED-COMPOUNDS

被引:61
作者
KROMER, W
机构
[1] Department of Pharmacology, Byk Gulden, Konstanz
关键词
ANTIULCER DRUGS; SUBSTITUTED BENZIMIDAZOLES; PROTON PUMP INHIBITORS; H+/K+-ATPASE; PANTOPRAZOLE; OMEPRAZOLE; LANSOPRAZOLE;
D O I
10.1159/000201275
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The novel antiulcer drugs omeprazole, lansoprazole, and pantoprazole are members of the class of substituted benzimidazoles. They potently inhibit the gastric proton pump by a common mechanism which depends on the acid-induced conversion of the parent compounds to the pharmacologically active principles: thiophilic cyclic sulfenamides. This transformation takes place in the luminal compartment of the secreting parietal cell. However, while the three proton pump inhibitors belong to the same chemical class, their two ring systems bear different functional substituents. This leads to essential modification of the physicochemical, metabolic, and pharmacokinetic properties of these drugs, possibly resulting in differences in tissue selectivity and thereby, in the long term, drug safety. Both preclinical and clinical data have accumulated that point to advantages of pantoprazole related to the above parameters: pantoprazole shows a higher stability at moderately acidic pH values and less inhibitory potential against cytochrome P450 than the other two drugs. In addition, pantoprazole displays linear pharmacokinetics with a high bioavailability.
引用
收藏
页码:443 / 454
页数:12
相关论文
共 89 条
[1]  
ALAWQATI Q, 1983, J EXP BIOL, V106, P135
[2]   A STUDY OF THE INTERACTION BETWEEN OMEPRAZOLE AND PHENYTOIN IN EPILEPTIC PATIENTS [J].
ANDERSSON, T ;
LAGERSTROM, PO ;
UNGE, P .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :329-333
[3]  
ANDERSSON T, 1991, Drug Investigation, V3, P45
[4]   EFFECT OF OMEPRAZOLE AND CIMETIDINE ON PLASMA DIAZEPAM LEVELS [J].
ANDERSSON, T ;
ANDREN, K ;
CEDERBERG, C ;
EDVARDSSON, G ;
HEGGELUND, A ;
LUNDBORG, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (01) :51-54
[5]   EFFECT OF OMEPRAZOLE TREATMENT ON DIAZEPAM PLASMA-LEVELS IN SLOW VERSUS NORMAL RAPID METABOLIZERS OF OMEPRAZOLE [J].
ANDERSSON, T ;
CEDERBERG, C ;
EDVARDSSON, G ;
HEGGELUND, A ;
LUNDBORG, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) :79-85
[6]   OMEPRAZOLE DRUG-INTERACTION STUDIES [J].
ANDERSSON, T .
CLINICAL PHARMACOKINETICS, 1991, 21 (03) :195-212
[7]   PHARMACOKINETICS OF VARIOUS SINGLE INTRAVENOUS AND ORAL DOSES OF OMEPRAZOLE [J].
ANDERSSON, T ;
CEDERBERG, C ;
REGARDH, CG ;
SKANBERG, I .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (02) :195-197
[8]   ABSENCE OF AN INHIBITORY EFFECT OF OMEPRAZOLE AND NIZATIDINE ON PHENYTOIN DISPOSITION, A MARKER OF CYP2C ACTIVITY [J].
BACHMANN, KA ;
SULLIVAN, TJ ;
JAUREGUI, L ;
REESE, JH ;
MILLER, K ;
LEVINE, L .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (04) :380-382
[9]   PANTOPRAZOLE - A NOVEL H+/K+-ATPASE INHIBITOR WITH AN IMPROVED PH STABILITY [J].
BEIL, W ;
STAAR, U ;
SEWING, KF .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 218 (2-3) :265-271
[10]  
BENET LZ, 1994, ALIMENT PHARM THERAP, V8, P25